Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Bharadwaj S, Lau E, Hamilton MP, Goyal A, Srinagesh H, Jensen A, Lee D, Mallampet J, Elkordy S, Syal S, Patil S, Latchford T, Sahaf B, Arai S, Johnston LJ, Lowsky R, Negrin R, Rezvani AR, Shizuru J, Meyer EH, Shiraz P, Mikkilineni L, Weng WK, Smith M, Sidana S, Muffly L, Maecker HT, Frank MJ, Mackall C, Miklos D, Dahiya S. Bharadwaj S, et al. Among authors: latchford t. J Immunother Cancer. 2024 Jul 1;12(7):e008975. doi: 10.1136/jitc-2024-008975. J Immunother Cancer. 2024. PMID: 38955420 Free PMC article.
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, Claire GK, Frank MJ, Muffly L, Shiraz P, Meyer E, Arai S, Brown JW, Johnston L, Lowsky R, Negrin RS, Rezvani AR, Weng WK, Latchford T, Sahaf B, Mackall CL, Miklos DB, Sidana S. Baird JH, et al. Among authors: latchford t. Blood Adv. 2021 Jan 12;5(1):143-155. doi: 10.1182/bloodadvances.2020002732. Blood Adv. 2021. PMID: 33570626 Free PMC article.
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Sidana S, Hosoya H, Jensen A, Liu L, Goyal A, Hovanky V, Sahaf B, Bharadwaj S, Latchford T, Arai S, Leahy S, Mei M, Budde LE, Muffly LS, Frank MJ, Dahiya S, Htut M, Miklos D, Janakiram M. Sidana S, et al. Among authors: latchford t. Blood Cancer J. 2023 Oct 13;13(1):158. doi: 10.1038/s41408-023-00929-0. Blood Cancer J. 2023. PMID: 37833271 Free PMC article. No abstract available.
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
Johnsrud A, Craig J, Baird J, Spiegel J, Muffly L, Zehnder J, Tamaresis J, Negrin R, Johnston L, Arai S, Shizuru J, Lowsky R, Meyer E, Weng WK, Shiraz P, Rezvani A, Latchford T, Mackall C, Miklos D, Frank M, Sidana S. Johnsrud A, et al. Among authors: latchford t. Blood Adv. 2021 Nov 9;5(21):4465-4475. doi: 10.1182/bloodadvances.2021004716. Blood Adv. 2021. PMID: 34521106 Free PMC article.